Cargando…

Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France

OBJECTIVES: Compare costs associated with all-cause healthcare resource use (HCRU), stroke/systemic thromboembolism (STE) and major bleedings (MB) between patients with non-valvular atrial fibrillation (NVAF) initiating apixaban or other oral anticoagulants (OACs). METHODS: We performed a retrospect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Belhassen, Manon, Hanon, Olivier, Steg, Philippe Gabriel, Mahé, Isabelle, Née, Mélanie, Jacoud, Flore, Dalon, Faustine, Cotté, François-Emery, Guitard-Dehoux, Dominique, Marant-Micallef, Claire, Van Ganse, Eric, Danchin, Nicolas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290596/ https://www.ncbi.nlm.nih.gov/pubmed/36030485 http://dx.doi.org/10.1007/s10198-022-01513-2

Ejemplares similares

Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study
por: Van Ganse, Eric, et al.
Publicado: (2020)

Trajectories of Controller Therapy Use Before and After Asthma-Related Hospitalization in Children and Adults: Population-Based Retrospective Cohort Study
por: Belhassen, Manon, et al.
Publicado: (2023)

EvaluatioN of ApiXaban in strOke and systemic embolism prevention in patients with non‐valvular atrial fibrillation in clinical practice Setting in France, rationale and design of the NAXOS: SNIIRAM study
por: Picard, Fabien, et al.
Publicado: (2019)

Differences in severe exacerbations rates and healthcare utilisation in COPD populations in the UK and France
por: Whittaker, Hannah, et al.
Publicado: (2022)

Cancer incidence and prevalence in cystic fibrosis patients with and without a lung transplant in France
por: Rousset-Jablonski, Christine, et al.
Publicado: (2022)

Impact of Therapy Persistence on Exacerbations and Resource Use in Patients Who Initiated COPD Therapy
por: Dalon, Faustine, et al.
Publicado: (2019)

Antipsychotic prescribing practices in real-life (APPREAL study): Findings from the French National Healthcare System Database (2007–2017)
por: Rolland, Benjamin, et al.
Publicado: (2022)

Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
por: Belhassen, Manon, et al.
Publicado: (2021)

Dual versus triple therapy in patients hospitalized for COPD in France: a claims data study
por: Dalon, Faustine, et al.
Publicado: (2019)

Treatment of Allergic Rhinitis and Asthma in Primary Care: Dispensations Do Not Align with Prescriptions
por: Belhassen, Manon, et al.
Publicado: (2022)

Cocooning strategy: Pertussis vaccination coverage rate of parents with a new-born in 2016 and 2017 in France
por: Marchal, Clarisse, et al.
Publicado: (2022)

Laboratory Assessment of the Anticoagulant Activity of Apixaban in Patients With Nonvalvular Atrial Fibrillation
por: Kyriakou, Elias, et al.
Publicado: (2018)

Mortality and Respiratory-Related Hospitalizations in Idiopathic Pulmonary Fibrosis Not Treated With Antifibrotics
por: Cottin, Vincent, et al.
Publicado: (2021)

Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation
por: Cirincione, Brenda, et al.
Publicado: (2018)

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

Spontaneous Spinal Epidural Hematoma in a Patient on Apixaban for Nonvalvular Atrial Fibrillation
por: El Alayli, Ahmad, et al.
Publicado: (2020)

Apixaban Concentrations in Routine Clinical Care of Older Adults With Nonvalvular Atrial Fibrillation
por: Thomas, Alveena, et al.
Publicado: (2022)

Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol
por: Colet, Josep Comín, et al.
Publicado: (2023)

Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation
por: Martinez, Brandon K., et al.
Publicado: (2018)

Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation
por: Brown, Joshua D., et al.
Publicado: (2016)

Patient satisfaction after switching from warfarin to apixaban in patients with nonvalvular atrial fibrillation: AGAIN study
por: Koretsune, Yukihiro, et al.
Publicado: (2017)

Use of analgesics in France, following dextropropoxyphene withdrawal
por: Van Ganse, E., et al.
Publicado: (2018)

Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups
por: Gómez-Outes, Antonio, et al.
Publicado: (2013)

Apixaban in Comparison to Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Observational Studies
por: Siddiqui, Muhammad U., et al.
Publicado: (2019)

Warfarin vs. apixaban in nonvalvular atrial fibrillation, and analysis by concomitant antiarrhythmic medication use: A national retrospective study
por: Wanat, Matthew A., et al.
Publicado: (2019)

A Systematic Review of Network Meta-Analyses and Real-World Evidence Comparing Apixaban and Rivaroxaban in Nonvalvular Atrial Fibrillation
por: Hill, Nathan R., et al.
Publicado: (2020)

Safety and effectiveness of apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A regulatory postmarketing surveillance, the STANDARD study
por: Inoue, Hiroshi, et al.
Publicado: (2019)

Appropriateness of rivaroxaban and apixaban dosing in hospitalized patients with a newly diagnosed nonvalvular atrial fibrillation at a single tertiary hospital
por: Alshibani, Mohannad
Publicado: (2023)

Safety and Effectiveness of Apixaban Versus Warfarin in Japanese Patients with Nonvalvular Atrial Fibrillation Stratified by Renal Function: A Retrospective Cohort Study
por: Morimoto, Takeshi, et al.
Publicado: (2023)

Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France
por: Cotté, François-Emery, et al.
Publicado: (2011)

Off-label reduced-dose apixaban does not reduce hemorrhagic risk in Taiwanese patients with nonvalvular atrial fibrillation: A retrospective, observational study
por: Chen, I-Chih, et al.
Publicado: (2021)

Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort study
por: Jaksa, Ashley, et al.
Publicado: (2022)

Venous Thromboembolism While on Anticoagulation With Apixaban
por: Mazahreh, Farah, et al.
Publicado: (2021)

Aftermath of Apixaban: Atypical Anticoagulation Aftereffect
por: Karki, Bhesh, et al.
Publicado: (2022)

Physician's Fear of Anticoagulant Therapy in Nonvalvular Atrial Fibrillation
por: Sen, Souvik, et al.
Publicado: (2014)

Apixaban Prophylactic Anticoagulation in Patients with Nephrotic Syndrome
por: Van Meerhaeghe, Tess, et al.
Publicado: (2022)

Incidence of venous thromboembolism in France: a retrospective analysis of a national insurance claims database
por: Bouée, Stéphane, et al.
Publicado: (2016)

Preparation of Apixaban Solid Dispersion for the Enhancement of Apixaban Solubility and Permeability
por: Lee, Juseung, et al.
Publicado: (2023)

Underuse of oral anticoagulants in patients with nonvalvular atrial fibrillation in Italy
por: Ferro, D., et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_oi5harjutisnhlprb5c1ah8j6s